Latest
Science & Space

Landmark Studies Find Blood Biomarker Could Help Detect Advanced CTE in Living Patients

New research published in JAMA shows plasma levels of eMTBR-tau were significantly elevated in former football players later confirmed at autopsy to have advanced CTE, though clinical testing is not yet available.

Read the story
Science & Space · Read the story
Newstro Science & Space section banner.
Newstro
Share this story

Breakthrough biomarker offers first blood-based signal of CTE during life

Boston — November 19, 2026 · 8:10 p.m. CST (02:10 UTC Nov. 20).

Scientists have moved closer to a long-sought blood test for chronic traumatic encephalopathy (CTE), publishing two landmark studies in JAMA showing that a specific tau protein fragment in blood plasma strongly tracks advanced stages of the degenerative brain disease in living patients, according to Scientific American and NBC New York.

For decades, CTE—a progressive condition linked to repetitive head impacts in football, combat, and other contact activities—could only be definitively diagnosed after death by examining brain tissue at autopsy. Finding a measurable signal in blood drawn during life represents a potential turning point for both diagnosis and future treatment trials.

Researchers led by Boston University’s CTE Center and Banner Health, alongside an independent companion study from Washington University School of Medicine in St. Louis, cautioned that the test remains in an early discovery phase and is not yet available for doctors or patients.

How the eMTBR-tau blood test works

In the Boston University–led study—published online Thursday in JAMA under the title “Plasma eMTBR-Tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology”—investigators examined blood samples collected during life from 21 former American football players who later donated their brains to the BU CTE Center Brain Bank.

The researchers measured plasma levels of eMTBR-tau (endogenously cleaved microtubule-binding region tau), a protein fragment previously studied in Alzheimer’s disease, and compared those readings against post-mortem brain pathology. They found eMTBR-tau concentrations were significantly elevated in donors confirmed at autopsy to have advanced, high-stage CTE compared with those who had low-stage or no CTE.

A separate Washington University case-control study published simultaneously in JAMA similarly linked blood levels of eMTBR-tau243 to CTE pathology, reinforcing the biomarker across two independent research teams. Dr. Michael Alosco, co-director of clinical research at the BU CTE Center and corresponding author, called the findings a potential “game changer,” according to the Boston Herald and New York Post.

Important caveats: small cohort and advanced disease only

Both research teams and outside neurologists stressed clear limits to the breakthrough. Because the Boston University analysis relied on 21 brain donors, far larger longitudinal studies will be needed to verify accuracy across diverse populations and separate CTE signals from Alzheimer’s disease or other tauopathies.

Equally important, the biomarker reliably distinguished advanced CTE rather than early-stage disease, meaning it cannot yet serve as a routine screening tool for young or active athletes, NBC Sports noted.

Still, researchers including BU CTE Center director Dr. Ann McKee, Dr. Thor Stein, Dr. Jesse Mez, Dr. Henrik Zetterberg, and Banner Health’s Dr. Nicholas Ashton view the discovery as an essential step toward running clinical trials for experimental therapies that could slow or treat CTE while patients are alive.

Boston University CTE Center medical campus

Much of the brain-bank correlation research took place through the Boston University CTE Center at the Chobanian & Avedisian School of Medicine in Boston’s South End, alongside collaborators at Banner Health and Washington University in St. Louis.

★ Boston University Medical Campus, home to the BU CTE Center in Boston, Mass. Map data: OpenStreetMap contributors, ODbL. Open map.

Sources and reporting credits

Sources: Scientific American, NBC New York, Boston Herald, NBC Sports, and New York Post, with study details from JAMA (November 19, 2026).

Visuals: Newstro.